What Gilead Saw for $3.15 Billion Before Anyone Else Did
Gilead paid $3.15 billion upfront for Tubulis before anyone outside the company saw the ovarian cancer data. At ASCO 2026, TUB-040 finally showed its cards: a 61% response rate and 11-month progression-free survival that could reshape the ADC landscape.
Imagine paying $3.15 billion for a restaurant based solely on a taste test. That's essentially what Gilead did when it agreed to acquire Tubulis, a German biotech, for up to $5 billion earlier this year. The meal in question? An antibody-drug conjugate (ADC) called TUB-040, which had promising but still-early data in ovarian cancer. Gilead signed the check before the rest of the world could see the menu.
On May 30, at ASCO 2026, the menu finally went public. And it looks like Gilead might have gotten a deal.
The Numbers That Justified a Mega-Deal
TUB-040 is designed to treat platinum-resistant ovarian cancer (PROC), one of the cruelest corners of oncology. These are patients whose cancer came back after platinum-based chemotherapy stopped working. Standard treatments in this setting buy about three to four months before the disease progresses again. That's the bar.
In the Phase I/IIa trial called NAPISTAR, TUB-040 cleared that bar by a wide margin. Among 46 patients treated at active dose levels (1.67 to 3.3 mg/kg), the confirmed response rate hit approximately 50%. Median progression-free survival landed at 11 months, roughly double what current options deliver.
To be clear, this is still early-stage data from a dose-escalation study, not a massive Phase 3 trial. But for a Phase 1/2 readout in a notoriously difficult cancer, those numbers turned heads. Gilead's chief medical officer, Dietmar Berger, noted the responses were "higher than what you see with other developments in the platinum-resistant area."
How TUB-040 Actually Works
Think of an ADC like a guided missile. You attach a cancer-killing payload to an antibody that knows exactly which cells to target. The antibody locks onto a specific protein on the tumor's surface, gets pulled inside the cell, and releases its toxic cargo. Healthy cells? Largely spared.
TUB-040's target is a protein called NaPi2b, which sits on the surface of the vast majority of ovarian cancer cells. That's important because it means most patients could potentially benefit, not just a narrow biomarker-selected slice.
Get tomorrow's biotech intelligence before your competitors.
Join thousands of biotech professionals who start their day with our free, daily briefing.
The warhead is a topoisomerase-I inhibitor (a drug that breaks DNA inside cancer cells, preventing them from replicating). What makes Tubulis special isn't just the missile or the warhead; it's the glue holding them together. Their proprietary P5 conjugation technology keeps the payload locked in place during transit through the bloodstream, reducing the chance it leaks out and damages healthy tissue before reaching the tumor.
This engineering difference showed up in the safety data. While the drug wasn't side-effect-free (neutropenia, a type of low white blood cell count, was among the notable adverse events), the trial reported no clinically significant lung toxicity and no clinically significant eye toxicity. That distinction matters enormously, because several competing ADCs carry those exact risks.
Why the Safety Profile Might Matter More Than the Response Rate
A roughly 50% confirmed response rate grabs the headline. But oncologists reading the ASCO poster were probably more excited about the toxicity profile. Here's why.
The current go-to ADC in ovarian cancer is mirvetuximab soravtansine (brand name Elahere), made by AbbVie after its $10.1 billion acquisition of ImmunoGen. Elahere works, but it causes ocular toxicity (eye problems) frequently enough that it complicates treatment. Other ADCs in development, particularly those using DXd-type payloads, carry risks of interstitial lung disease, a potentially serious inflammatory condition in the lungs.
TUB-040 appears to dodge both of those problems. If that holds up in larger trials, it opens a door that could be even more valuable than the platinum-resistant setting alone: combination therapy in earlier lines of treatment. A cleaner safety profile makes those combinations far more feasible.
Moving a drug from late-line rescue therapy to earlier, first-line treatment is how you turn a niche product into a blockbuster. Gilead knows this playbook well; it's the same strategy they've pursued with Trodelvy in breast cancer.
The Ovarian Cancer ADC Arms Race
TUB-040 isn't entering a quiet neighborhood. The ovarian cancer ADC space has become one of the most competitive arenas in oncology, with at least 10 programs in active development across multiple targets.
Elahere (AbbVie) is the incumbent, but it requires patients to have high levels of folate receptor alpha (FRα) expression, which limits its addressable population. Challengers like rinatabart sesutecan from Genmab (acquired through its $1.8 billion ProfoundBio deal) are showing roughly 50% response rates across a broader range of FRα expression levels, potentially capturing patients Elahere can't reach.
Then there's AstraZeneca and Daiichi Sankyo, who aren't content with dominating breast cancer ADCs. They're developing three different ADCs relevant to ovarian cancer: one targeting FRα, one targeting TROP2, and Enhertu for HER2-positive solid tumors (which already has a tumor-agnostic approval).
TUB-040 sidesteps this entire FRα dogfight by targeting NaPi2b instead. That's a different protein entirely, which means TUB-040 could potentially work in patients who've already tried (and failed) FRα-targeted therapies. In a world where oncologists are increasingly thinking about how to sequence multiple ADCs one after another, having a different target is a genuine competitive advantage.
What Gilead Is Really Building
Zoom out from TUB-040 and the Tubulis acquisition starts looking less like a drug deal and more like an infrastructure investment. Gilead isn't just buying one clinical asset. They're buying a platform.
Tubulis' P5 conjugation technology can theoretically be applied to different antibodies and different payloads, generating a pipeline of future ADCs. Gilead has explicitly said the technology could extend beyond oncology into inflammation and virology, their traditional strongholds. They're even converting Tubulis' Munich headquarters into a dedicated ADC innovation hub.
This fits a pattern. In 2026 alone, Gilead has announced three acquisitions totaling over $15 billion: Tubulis for ADCs, Arcellx (~$7.8 billion) for a next-generation CAR-T cell therapy in multiple myeloma, and Ouro Medicines (~$1.7 billion) for T-cell engagers targeting autoimmune diseases. Add in recently exercised options with Cartography Biosciences (tumor-selective antigens that could feed future ADC programs) and Kymera Therapeutics (targeted protein degraders), and the picture becomes clear.
Gilead is systematically assembling a multi-modality oncology machine. ADCs, cell therapies, bispecifics, degraders: they want all of it. The company has stated a goal of growing oncology into a $10 billion-plus franchise by the early 2030s, with Trodelvy (which generated approximately $1.3 billion in 2024 sales) as the commercial foundation.
The $3.15 Billion Question
Is TUB-040 worth what Gilead paid? That depends on which version of the future you believe in.
In the optimistic scenario, Phase 3 confirms the Phase 1/2 numbers, TUB-040 wins approval in platinum-resistant ovarian cancer, then expands into earlier treatment lines and possibly NSCLC (where it's also being tested). The P5 platform spawns additional ADC candidates. Gilead ends up with a durable, multi-billion-dollar ADC franchise that complements Trodelvy. The $3.15 billion upfront looks like a bargain.
In the cautious scenario, ADC history offers plenty of warnings. Strong early-phase response rates have a habit of shrinking in larger, randomized trials. Neutropenia rates could complicate combinations with chemotherapy. Designing a Phase 3 trial that satisfies regulators and demonstrates clear superiority over a rapidly evolving standard of care is never straightforward. The details of the pivotal trial design will matter enormously.
Analyst commentary has settled on a phrase that captures both sides neatly: "strategically sound but execution-sensitive." The ASCO data make the acquisition look smart. But smart acquisitions can still stumble in Phase 3.
What Happens Next
The clock is now ticking on several fronts. Gilead needs to finalize the Phase 3 trial design with the FDA, likely targeting initiation around 2027. Meanwhile, TUB-040's combination studies in earlier-line ovarian cancer will provide signals about whether the favorable safety profile holds when you layer on additional toxic drugs.
The broader ovarian cancer ADC landscape will also continue to shift. Every data readout from Genmab's rinatabart sesutecan, AstraZeneca's AZD-5335, and other competitors will recalibrate the competitive picture. TUB-040's NaPi2b target gives it some insulation from direct head-to-head comparisons, but ultimately, oncologists will choose the drug that offers the best balance of efficacy, safety, and convenience for their patients.
For now, Gilead can point to ASCO 2026 as validation. They bet $3.15 billion on a taste test, and the first real meal delivered. Whether this turns into a Michelin-star franchise or a cautionary tale about overpaying for promise will take a few more years to resolve. The early reviews, though? Pretty favorable.
Funding & Financings
5 min read
Biotech's Favorite New Trick for Pretending Everything Is Fine
Biotech startups are dodging down rounds by reopening old funding rounds instead of raising new ones. It's clever financial engineering, but the strategy reveals just how much stress still lurks beneath the surface of private biotech markets.
